sponsored
PatientsVille.com Logo

PatientsVille

Polymyalgia Rheumatica Medical Research Studies

Up-to-date List of Polymyalgia Rheumatica Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Polymyalgia Rheumatica Medical Research Studies

Rank Status Study
1 Recruiting Study of Tocilizumab to Treat Polymyalgia Rheumatica
Condition: Polymyalgia Rheumatica (PMR)
Intervention: Drug: Tocilizumab
Outcome Measures: Proportion of Patients in Disease Remission at Six Months from Trial Entry;   Number of Participants with Adverse Events as a Measure of Safety and Tolerability;   Proportion of patients able to achieve Disease Remission (DR) off corticosteroids, without Disease Relapse or Recurrence;   Proportion of patients who develop Disease Relapses;   The proportion of patients who develop Disease Recurrences;   The cumulative dose of prednisone
2 Unknown  Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica
Condition: Polymyalgia Rheumatica
Interventions: Drug: Betamethasone;   Drug: isotonic sodium chloride solution (placebo)
Outcome Measure: a total dose of glucocorticoids used in the course of the disease
3 Recruiting Tocilizumab Effect iN Polymyalgia Rheumatica
Condition: Polymyalgia Rheumatica
Intervention: Drug: TCZ
Outcome Measures: Efficacy at W12;   Safety and efficacy during the study
4 Recruiting Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis
Condition: Temporal Arteritis
Intervention:
Outcome Measures: Discover biomarkers in Giant cell arteritis capable of measuring disease activity and response to treatment.;   Measure the predictive value of biomarkers for clinical outcome in Giant cell arteritis.
5 Recruiting Tocilizumab for Patients With Giant Cell Arteritis
Condition: Giant Cell Arteritis
Interventions: Drug: Tocilizumab + Glucocorticoids (GCs);   Drug: Placebo + Glucocorticoids (GCs)
Outcome Measures: Proportion of patients that have achieved complete remission of disease;   Proportion of relapse free patients;   Cumulative dose of GCs in mg;   Time to first relapse after induction of remission
6 Recruiting Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis
Conditions: Takayasu's Arteritis;   Giant Cell Arteritis;   Arteritis;   Vasculitis;   Aortitis
Intervention:
Outcome Measure: Correlation between carotid IMT and neovascularization and disease activity
7 Recruiting Prospective Follow-up Study of the Aortic Diameter in Patients With Giant Cell Arteritis
Condition: Giant Cell Arteritis
Intervention:
Outcome Measures: Diameter of aorta.;   Volume of aorta
8 Recruiting Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
Conditions: Horton's Disease;   Infectious Disease;   Neoplasia;   Solid Tumor;   Hemopathy
Interventions: Other: 1 blood sample;   Other: 2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)
Outcome Measures: Quantification of specific cytokines of the Th17 immune response (IL-17 A and IL-23) in the serum;   Quantification of LTh17 by flow cytometry;   Measurement of the activation level of genes specifically involved in Th17 response using RT-PCR on frozen mRNA;   Measure the ability of Treg to proliferate and to synthesize IL-17 in response to different antigenic stimulations
9 Recruiting Study of the T CD8 Immune Response in Horton's Disease
Condition: Horton's Disease
Interventions: Other: Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment;   Other: 16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment;   Other: Blood sample drawn into a 5 mL dry tube;   Other: 16 blood samples drawn into 6 mL heparinized tubes
Outcome Measure: The percentage of cytotoxic T lymphocytes CD8 (CD8+perforin+granzyme B+)
10 Recruiting A Study of RoActemra/Actemra (Tocilizumab) in Patients With Giant Cell Arteritis
Condition: Giant Cell Arteritis
Interventions: Drug: prednisone;   Drug: prednisone placebo;   Drug: tocilizumab placebo;   Drug: tocilizumab [RoActemra/Actemra]
Outcome Measures: Proportion of patients in sustained remission at Week 52 (TCZ + 26 weeks prednisone taper versus placebo + 26 weeks prednisone taper);   Proportion of patients in sustained remission at Week 52 (TCZ + 26 weeks prednisone taper versus placebo + 52 weeks prednisone taper);   Time to giant cell arteritis disease flare after clinical remission (TCZ + 26 weeks prednisone taper versus placebo + 26 and 52 weeks prednisone taper);   Total cumulative prednisone dose (TCZ + 26 weeks prednisone taper versus placebo + 26 and 52 weeks prednisone taper);   Patient reported outcome: Short form SF-36 questionnaire (TCZ + 26 weeks prednisone taper versus placebo + 26 and 52 weeks prednisone taper);   Patient reported outcome: Patient global assessment (PGA) of disease activity on visual analogue scale (VAS) (TCZ + 26 weeks prednisone taper versus placebo + 26 and 52 weeks prednisone taper);   Pharmacokinetics: Area under the concentration-time curve (AUC) of tocilizumab in combination with 26 week tapering prednisone;   Pharmacokinetics: Tocilizumab concentrations in combination with 26 week tapering prednisone (Cmin, Cmax, Ctrough);   Pharmacodynamics: Interleukin 6/sIL-6R/ESR/CRP;   Safety: Incidence of adverse events;   Incidence of anti-tocilizumab antibodies
11 Recruiting Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL)
Condition: Giant Cell Arteritis
Interventions: Procedure: Ultrasound of temporal and axillary arteries;   Procedure: Temporal artery biopsy
Outcome Measures: To evaluate the diagnostic accuracy (sensitivity and specificity) of ultrasound as an alternative to temporal artery biopsy for the diagnosis of GCA in patients referred for biopsy with suspected GCA.;   To evaluate the cost-effectiveness (incremental cost per QALY) of ultrasound instead of biopsy in the diagnosis of GCA.;   To evaluate inter-observer agreement in the assessment of ultrasound and temporal artery biopsy;   To elicit expert views on the appropriateness of performing a biopsy following ultrasound using clinical vignettes;   To evaluate the diagnostic accuracy (sensitivity and specificity) of the sequential diagnostic strategy as an alternative to temporal artery biopsy alone in the diagnosis of GCA;   To evaluate the cost-effectiveness (incremental cost per QALY) of the diagnostic strategy of combined ultrasound and biopsy instead of biopsy alone in the diagnosis of GCA.;   Specific adverse events measured at each assessment; daily and cumulative steroid dose; steroid side effects; and pain or dysaesthesia at the biopsy site.;   Evolution of an alternative diagnosis;   Negative predictive value of ultrasound in preventing the need for temporal artery biopsies.;   Cost analysis of performing a screening ultrasound examination plus biopsy as part of the diagnostic workup of all patients with suspected GCA; or of performing a screening ultrasound examination instead of biopsy; or of performing a screening ultrasound;   Cost analysis of performing a screening ultrasound examination instead of biopsy in cases with a very low probability of GCA as part of the diagnostic workup of all patients with suspected GCA.;   Prediction of potential harm done to patients by over diagnosis or under diagnosis of GCA as a result of ultrasound use, either alone or in combination with biopsy;   Value of axillary artery ultrasound scanning in contributing to the diagnosis of GCA.;   Analysis of proportion of patients with a biopsy positive halo, stenosis, or occlusion assessed by high resolution ultrasound;   Presence of characteristic features of GCA on temporal artery biopsy in relation to clinical and ultrasound findings
12 Recruiting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg Strauss Syndrome;   Polyarteritis Nodosa;   Giant Cell Arteritis;   Takayasu Arteritis
Intervention:
Outcome Measure: Develop new diagnostic and classification criteria for ANCA associated vasculitis and polyarteritis nodosa
13 Recruiting Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Horton's Disease: Proof of Concept Study.
Condition: Horton's Disease
Intervention: Drug: corticoids+ tocilizumab 8mg/Kg/month
Outcome Measure: Percentage of Treg
14 Recruiting One-Time DNA Study for Vasculitis
Conditions: Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss);   Giant Cell Arteritis;   Granulomatosis With Polyangiitis (Wegener's);   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
Intervention:
Outcome Measure: Evaluation of clinical data and linked DNA specimens.
15 Unknown  Sensitivity and Specificity of Color Doppler Directed Temporal Artery Biopsy as Compared to Standard Random Biopsy in the Diagnosis of Temporal Arteritis
Conditions: Temporal Arteritis;   Duplex of Temporal Artery;   Biopsy of Temporal Artery
Intervention: Procedure: biopsy of temporal artery
Outcome Measure:
16 Recruiting Magnetic Resonance Angiography vs Ultrasonography in Systemic Large vEssel vasculitiS
Condition: Systemic Vasculitis
Interventions: Device: Ultrasound;   Device: MRA
Outcome Measures: Accuracy of CDUS vs MRA in the assessment of the IMC thickness of the supra-aortic vessels in patients with sLVV.;   Measurement of the the average IMC thickness of aorta, carotid, subclavian, vertebral, axillary and temporal arteries in a population of healthy individuals.;   Cellular, cytokine and genetic abnormalities in sLVV patients compared to the control group of healthy individuals
17 Unknown  Diagnostic Study of Temporal Arteritis
Condition: Temporal Arteritis
Intervention:
Outcome Measures: Percent decrease in future biopsy use.;   No secondary outcome.

These studies may lead to new treatments and are adding insight into Polymyalgia Rheumatica etiology and treatment.

A major focus of Polymyalgia Rheumatica research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Polymyalgia Rheumatica